Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II study of OSE-127 for Sjogren's syndrome

Trial Profile

A Phase II study of OSE-127 for Sjogren's syndrome

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2018

At a glance

  • Drugs OSE 127 (Primary)
  • Indications Sjogren's syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Nov 2018 According to an OSE Immunotherapeutics media release, the company has signed a license option agreement with Servier in Dec 2016 for the development and commercialization of OSE-127, up to the completion of a phase 2 clinical trial, planned in ulcerative colitis (CT profile 280156) and in parallel in Sjogrens syndrome.
    • 10 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top